3 results
Approved WMOPending
To assess the effectivity and safety of 1.0 molar gadobutrol (Gadovist®) for breast MRI
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
Approved WMOPending
To prospectively assess the potential effect of repeated exposure to either a linear or amacrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 inmotor and cognitive function among neurologically normal adults in…